NishaAcharyaMD

Ophthalmology • San Francisco, CA

Uveitis

Professor, Department of Ophthalmology and Epidemiology Director of Uveitis Service, Proctor Foundation University of California San Francisco

Join to view full profile

Dr. Acharya is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Acharya's full profile

Already have an account?

Office
95 Kirkham St
San Francisco, CA 94122
Phone+1 415-476-1442

Education & Training

University of California (San Francisco)Fellowship, Cornea, External Diseases, and Refractive Surgery, 2004 - 2006
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 2001 - 2004
Brigham and Women's HospitalInternship, Internal Medicine, 2000 - 2001
University of California San Francisco School of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2004 - 2025
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Steroids for Corneal Ulcers Trial Start of enrollment: 2006 Sep 01
Completed
Phase 4
Lucentis for Inflammatory Macular Edema Trial Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer Start of enrollment: 2007 Nov 01
Completed
Phase 1, Phase 2
Mycotic Ulcer Treatment Trial I Start of enrollment: 2010 Apr 01
Completed
Phase 3
The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo Start of enrollment: 2010 May 01
Completed
Phase 3
Methotrexate and Mycophenolate Mofetil for UVEITIS Start of enrollment: 2013 Aug 01
Completed
Phase 3
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Start of enrollment: 2018 Sep 12
Terminated
Phase 4
Adalimumab in JIA-associated Uveitis Stopping Trial Start of enrollment: 2020 Mar 15
Active, not recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

Recombinant zoster vaccine and the risk of dementia.
Emily Tang, Isabel Ray, Benjamin F Arnold, Nisha R Acharya
Vaccine. 2025-02-06
Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease.
Miel Sundararajan, Sivakumar R Rathinam, Radhika Thundikandy, Anuradha Kanakath, S Balamurugan
Ocular Immunology and Inflammation. 2025-02-01
1 citations
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
Nisha R Acharya, Athimalaipet V Ramanan, Alison B Coyne, Kathryn L Dudum, Elia M Rubio
Lancet. 2025-01-25

Press Mentions

Adalimumab: To Stop or Not to Stop for Juvenile Idiopathic Arthritis–Associated Uveitis?January 30th, 2025
Uveitis History Linked to Recurrence After COVID VaccinationApril 25th, 2024
Two Commonly Used Uveitis Drugs Perform Similarly in NIH-Funded Clinical TrialSeptember 11th, 2019
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow